Beta blockers for peripheral arterial disease
References
Additional references
Anonymous. American College of Cardiologists/American Heart Association Guidelines: Class 1 indications of beta‐blockers. www.acc.org (accessed on 12 December 2003).
Joint Formularly Committee. British National Formulary. Vol. 46, London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2003.
Criqui MH, Fronek A, Barrett‐Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3):510‐5.
Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. British Medical Journal 1978;1(6124):1379‐81.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12.
Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. Journal of the American Geriatrics Society 1985;33(1):13‐8.
Lassila R, Lepantalo M, Lindfors O. Peripheral arterial disease‐‐natural outcome. Acta Medica Scandinavica 1986;220(4):295‐301.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.
